Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma
Authors
Halwani, A. S.Panizo, C.
Isufi, I.
Herrera, A. F.
Okada, C. Y.
Cull, E. H.
Kis, B.
Chaves, J. M.
Bartlett, N. L.
Ai, W.
de la Cruz-Merino, L.
Bryan, L. J.
Houot, R.
Linton, Kim M
Briones, J.
Chau, I.
von Keudell, G. R.
Lu, H.
Yakovich, A.
Chen, M.
Meulen, J. H. T.
Yurasov, S.
Hsu, F. J.
Flowers, C. R.
Affiliation
Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USAIssue Date
2021
Metadata
Show full item recordCitation
Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, et al. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma Leukemia & Lymphoma. Informa UK Limited; 2021. p. 1–13.Journal
Leukemia and LymphomaDOI
10.1080/10428194.2021.2010057PubMed ID
34865586Type
Articleae974a485f413a2113503eed53cd6c53
10.1080/10428194.2021.2010057
Scopus Count
Collections
Related articles
- Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study.
- Authors: Spalato-Ceruso M, Bouteiller F, Guegan JP, Toulmonde M, Bessede A, Kind M, Cousin S, Buy X, Palussiere J, Le Loarer F, Dadone-Montaudie B, Pulido M, Italiano A
- Issue date: 2022 Oct 27
- Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma.
- Authors: Bhatia S, Miller NJ, Lu H, Longino NV, Ibrani D, Shinohara MM, Byrd DR, Parvathaneni U, Kulikauskas R, Ter Meulen J, Hsu FJ, Koelle DM, Nghiem P
- Issue date: 2019 Feb 15
- Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
- Authors: Diefenbach C, Kahl BS, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke JM, Hirata J, Jiang Y, Paulson JN, Chang YM, Musick L, Abrisqueta P
- Issue date: 2021 Dec
- Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A.
- Authors: Lu H, Betancur A, Chen M, Ter Meulen JH
- Issue date: 2020
- Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
- Authors: Lakhani NJ, Chow LQM, Gainor JF, LoRusso P, Lee KW, Chung HC, Lee J, Bang YJ, Hodi FS, Kim WS, Santana-Davila R, Fanning P, Squifflet P, Jin F, Kuo TC, Wan HI, Pons J, Randolph SS, Messersmith WA
- Issue date: 2021 Dec